Enveric Biosciences, Inc. (ENVB) AI Stock Analysis

Enveric Biosciences, Inc. is a biotechnology company focused on developing small-molecule therapeutics aimed at treating anxiety, depression, and addiction disorders. Leveraging its discovery and development platform, The Psybrary, the company has assembled a portfolio of novel chemical entities tailored for specific mental health indications. Its research is led by the EVM201 series, featuring synthetic psilocybin analogues designed as prodrugs of psilocin, and the third-generation EVM301 Series targeting central nervous system disorders. Headquartered in Naples, Florida, with offices in Cambridge, Massachusetts, and Calgary, Canada, the company employs 5 people.

Annual revenue grew from $36.1M in FY2016 to $48.6M in FY2017, before declining to $43.0M in FY2018 and holding at $39.9M in both FY2019 and FY2020. Annual net income was negative throughout this span, reporting -$2.8M in FY2016, -$16.9M in FY2018, and -$6.9M in FY2020. Gross margin fell to -0.3% in FY2020, with R&D expense at $174,083. For the 5-year period from FY2015 to FY2020, revenue CAGR was 20.1%. For the trailing twelve months ended June 30, 2026, revenue stood at $35.4M, with quarterly revenue growth declining 7.3% year-over-year. Trailing operating margin was 0.0%, and return on equity was -170.0%.

As of June 30, 2026, Enveric Biosciences held $8.3M in cash and short-term investments, with total assets of $8.9M and shareholders' equity of $8.1M. The company reported a current ratio of 10.21. In FY2025, capital expenditures were $3, while dividends paid totaled $3.4M. Over a 5-year period, the company's share count increased by 10229.3%.

At a share price of $1.38 as of October 16, 2026, Enveric Biosciences has a market cap of $6.2M and an enterprise value of -$1.4M. Its forward P/E ratio of 23.1x compares to 17.3x for the median of its US-listed Healthcare peers. The stock trades at a price-to-sales multiple of 0.1x against the peer group median of 4.1x, and an EV/EBITDA of 0.3x versus the peer median of 12.0x. Over the past year, ENVB shares dropped 85.4%, while the S&P 500 gained 16.8%. Over five years, the stock returned -100.0% compared to an 83.0% gain for the index.

Analysts maintain a mean price target of $10.00 for ENVB, which stands 624.6% above its last closing price of $1.38. For the next fiscal year, estimates call for revenue of $0 and EPS of $0.00. The company beat EPS estimates in 1 of the last 4 quarters. The next earnings report is scheduled for November 13, 2026.

This page is an AI-written research summary of Enveric Biosciences, Inc. (ENVB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ENVB income statement, ENVB balance sheet, ENVB key metrics, ENVB analyst forecast, ENVB chart. See the ENVB stock overview for the latest quote and news.